In addition to these preclinical studies, four groups carried out clinical trials in which CRC was treated with CAR-T cells targeting HER2 [11], TAG-72 [12], CEA [13], or CEACAM5 [14]. Here, CEACAM5 is linked to colorectal carcinoma.